TY - JOUR
T1 - Safety of mRNA-based COVID-19 vaccination in paediatric patients with a PEG-asparaginase allergy
AU - Broos, Nancy
AU - Brigitha, Leiah
AU - Schuurhof, Annemieke
AU - Röckmann-Helmbach, Heike
AU - Tissing, Wim
AU - Pieters, Rob
AU - van der Sluis, Inge
AU - Stadermann, Marieke
N1 - © 2022 The Authors.
PY - 2023
Y1 - 2023
N2 - Background:
Children treated for a malignancy are at risk to develop serious illness from a COVID-19 infection. Pegylated E.coli asparaginase (PEG-asparaginase) is used in the treatment of acute lymphoblastic leukemia. Allergy to this drug is common and both asparaginase and polyethylene glycol (PEG) are identified as possible antigens. The mRNA-based vaccines against COVID-19 contain PEG as a stabilizing component.
Methods:
We developed a protocol to be able to safely vaccinate children with a PEG-asparaginase allergy. All patients with a history of allergy to PEG-asparaginase have been included and skin prick testing for various PEGs was performed before vaccination with the mRNA Pfizer-BioNTech COVID-19 vaccine.
Results:
Twelve children between six and 16 years old were vaccinated, without allergic reaction. None of them got a positive skin prick test for PEG. Ten patients had pre-existing IgG or IgM antibodies against PEG.
Conclusion:
Children with a PEG-asparaginase allergy can be safely vaccinated against COVID-19 with mRNA vaccines containing PEG irrespective of IgG/IgM antibodies to PEG-asparaginase. Routine skin prick testing in patients with PEG-asparaginase allergy does not seem to be of added value.
AB - Background:
Children treated for a malignancy are at risk to develop serious illness from a COVID-19 infection. Pegylated E.coli asparaginase (PEG-asparaginase) is used in the treatment of acute lymphoblastic leukemia. Allergy to this drug is common and both asparaginase and polyethylene glycol (PEG) are identified as possible antigens. The mRNA-based vaccines against COVID-19 contain PEG as a stabilizing component.
Methods:
We developed a protocol to be able to safely vaccinate children with a PEG-asparaginase allergy. All patients with a history of allergy to PEG-asparaginase have been included and skin prick testing for various PEGs was performed before vaccination with the mRNA Pfizer-BioNTech COVID-19 vaccine.
Results:
Twelve children between six and 16 years old were vaccinated, without allergic reaction. None of them got a positive skin prick test for PEG. Ten patients had pre-existing IgG or IgM antibodies against PEG.
Conclusion:
Children with a PEG-asparaginase allergy can be safely vaccinated against COVID-19 with mRNA vaccines containing PEG irrespective of IgG/IgM antibodies to PEG-asparaginase. Routine skin prick testing in patients with PEG-asparaginase allergy does not seem to be of added value.
UR - https://www.mendeley.com/catalogue/2c5e0776-392b-39ff-b515-65f5e2c5c5dc/
U2 - 10.1016/j.ejcped.2022.100002
DO - 10.1016/j.ejcped.2022.100002
M3 - Article
C2 - 38013843
SN - 2772-610X
VL - 1
SP - 100002
JO - EJC Pediatric Oncology
JF - EJC Pediatric Oncology
ER -